| Description |
LY377604 is a human β3-adrenergic receptor agonist with an EC50 of 2.4 nM and also a β1- and β2-adrenergic receptor antagonist.
|
| Related Catalog |
|
| Target |
EC50: 2.4 nM (human β3-adrenergic receptor)[1] β1-adrenergic receptor, β2-adrenergic receptor[1]
|
| In Vitro |
LY377604 is a human β3-adrenergic receptor agonist with an EC50 of 2.4 nM and also a β1- and β2-adrenergic receptor antagonist. LY377604 causes a maximal increase in cyclic adenosine monophosphate (cAMP) levels, but does not stimulate cAMP accumulation in CHO cells transfected with either the human β1 adrenergic receptor or the human β2 adrenergic receptor[1].
|
| In Vivo |
Administration of LY377604 to male Long-Evans rats fed a caloric dense diet results in stimulation of lipid utilization. This is observed as a decrease in respiratory quotient and persists for about 4 h before returning to that measured from vehicle-treated rats[1].
|
| References |
[1]. Jesudason CD, et al. Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity. ACS Med Chem Lett. 2011 May 23;2(8):583-6.
|
